David Shin, MD, is a trained physician and engineer who brings over 20 years of investment management and executive operating experience to BioAdvance. His career includes deep focus in both therapeutics and software development for the life sciences, which enables him to support a diverse group of companies in the BioAdvance portfolio.
At Catalytic Life Sciences, a biotech consulting firm, Dr. Shin assisted private-stage, therapeutics clients with company strategy, business development, and preparations for fundraising. At Limelight Bio, as Chief Operating Officer, he was instrumental in establishing complementary gene therapy platforms that later became the foundations for two new companies. Prior to Limelight, Dr. Shin was VP of Strategy at Alpine Biosciences, a nanotechnology platform company focused on the delivery of large molecules, which was eventually sold to Oncothyreon in 2014.
In 2008, Dr. Shin helped launch Ayer Capital, a long-short, healthcare hedge fund based in San Francisco. During this time, he managed investments in therapeutics, diagnostics, and device companies for the fund.
After his clinical training, Dr. Shin’s initial industry experience was in software and services for drug development. He held a leadership role at InnaPhase Corporation, a venture-backed company in Philadelphia which was acquired by Thermo Fisher in 2004. He remained there as Director of Technology in the Informatics division, which was responsible for integrating data across the entirety of Thermo’s product and service offerings.
Dr. Shin earned his BS in Electrical Engineering from Carnegie Mellon and his MD from the University of Pennsylvania where he also trained in ophthalmology. During residency, his research and publications centered on computer vision and augmented reality applications for ophthalmology.